Aurora Cannabis (US) (ACB)
NASDAQ:ACB
ACB Stock Chart & Stats
$3.66
-$0.24(-5.15%)
At close: 4:00 PM EST
$3.66
-$0.24(-5.15%)
Day’s Range― - ―
52-Week Range$2.73 - $6.67
Previous Close$4.5
Volume634.82K
Average Volume (3M)845.76K
Market Cap
$181.74M
Enterprise Value$144.59M
Total Cash (Recent Filing)$164.69M
Total Debt (Recent Filing)$23.86M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 12, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding61,942,146
10 Day Avg. Volume1,252,053
30 Day Avg. Volume845,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue0.45
Enterprise Value/Gross Profit1.44
Enterprise Value/Ebitda14.72
Forecast
1Y Price Target
$4.11Price Target Upside12.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$206.85M
Bulls Say, Bears Say
Bulls Say
International Medical Market LeadershipA majority international revenue mix and double-digit FY2026 top-line growth reduce dependence on the weak Canadian consumer market. Durable medical focus in Europe, Australia and NZ and EU‑GMP capacity give structural access to higher‑margin, regulated markets and support steadier long‑term demand.
Strong Adjusted Margins And EBITDA GrowthIndustry-leading gross margins and a material rise in adjusted EBITDA signal sustainable operating leverage from higher-margin medical products and cost discipline. These margin dynamics provide a buffer against price shocks and fund reinvestment in international expansion over the medium term.
Healthy Liquidity And Reduced LeverageA strong cash position, sharply reduced debt and an active shelf/ATM give durable financial flexibility. This balance sheet strength supports capacity investments (EU‑GMP, Leuna expansion), allows the firm to absorb transitional revenue shocks and pursue accretive M&A without immediate dilution pressure.
Bears Say
Canadian Reimbursed‑rate CutA regulatory-driven ~30% cut to reimbursed pricing materially and persistently reduces Canadian medical revenue and margins. Given Canada’s historic importance, this structural policy shift forces portfolio exits and a strategic reset that will depress consolidated revenue and EBITDA through FY2027 and beyond if unchanged.
Inconsistent Cash GenerationRecurrent negative operating and free cash flow undermines self-funding for growth and increases reliance on capital markets. Even with current liquidity, inconsistent cash generation raises execution risk for capacity expansions and M&A, and limits resilience to prolonged market or regulatory headwinds.
Volatile Revenue And Recurring LossesA return to sizable losses and recent revenue declines show earnings fragility. Volatile top line and collapsing gross profit reflect sensitivity to pricing, mix and cost factors; sustained profitability will require durable margin recovery and consistent sales across markets to protect equity value.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis (US)’s price range in the past 12 months?
Aurora Cannabis (US) lowest stock price was $2.73 and its highest was $6.67 in the past 12 months.
What is Aurora Cannabis (US)’s market cap?
Aurora Cannabis (US)’s market cap is $181.74M.
When is Aurora Cannabis (US)’s upcoming earnings report date?
Aurora Cannabis (US)’s upcoming earnings report date is Aug 12, 2026 which is in 53 days.
How were Aurora Cannabis (US)’s earnings last quarter?
Aurora Cannabis (US) released its earnings results on Jun 11, 2026. The company reported -$0.343 earnings per share for the quarter, missing the consensus estimate of -$0.041 by -$0.302.
Is Aurora Cannabis (US) overvalued?
According to Wall Street analysts Aurora Cannabis (US)’s price is currently Undervalued.
Does Aurora Cannabis (US) pay dividends?
Aurora Cannabis (US) does not currently pay dividends.
What is Aurora Cannabis (US)’s EPS estimate?
Aurora Cannabis (US)’s EPS estimate is -0.1.
How many shares outstanding does Aurora Cannabis (US) have?
Aurora Cannabis (US) has 61,942,146 shares outstanding.
What happened to Aurora Cannabis (US)’s price movement after its last earnings report?
Aurora Cannabis (US) reported an EPS of -$0.343 in its last earnings report, missing expectations of -$0.041. Following the earnings report the stock price went down -6.383%.
Which hedge fund is a major shareholder of Aurora Cannabis (US)?
Currently, no hedge funds are holding shares in ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.11 (12.43% Upside)
$4.11 (12.43% Upside)
Blogger Sentiment
Bullish
ACB Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▼ 18.1%
Last 30 Days ▼ 18.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.39%
12-Months-Change
Fundamentals
Return on Equity
-14.05%
Trailing 12-Months
Asset Growth
-27.30%
Trailing 12-Months
Company Description
Aurora Cannabis (US)
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
ACB Company Deck
ACB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial performance for FY2026 — double-digit revenue growth, strong adjusted gross margins (64%), 32% growth in adjusted EBITDA to CAD 54M, solid international momentum, accretive M&A (Safari) and a strong cash position (CAD 165M, no debt). However, the company signaled a near-term reset driven by a material (~30%) reduction in Canadian reimbursed pricing effective April 1, which will pressure FY2027 revenue, margins (guidance to mid-to-high 50s) and annual adjusted EBITDA despite targeted investments in higher-margin international markets. Overall, strong historic execution and balance sheet strength outweigh the headwinds, but FY2027 is expected to be transitional as management reallocates resources and expands EU GMP capacity.View all ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
$4.11
▲(12.43% Upside)
Technical Analysis
Ownership Overview
0.49% Insiders
0.10% Mutual Funds
1.41% Other Institutional Investors
94.25% Public Companies and
Individual Investors